Eli Lilly Net Worth
Eli Lilly Net Worth Breakdown | LLY |
Eli Lilly Net Worth Analysis
Eli Lilly's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Eli Lilly's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Eli Lilly's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Eli Lilly's net worth analysis. One common approach is to calculate Eli Lilly's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Eli Lilly's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Eli Lilly's net worth. This approach calculates the present value of Eli Lilly's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Eli Lilly's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Eli Lilly's net worth. This involves comparing Eli Lilly's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Eli Lilly's net worth relative to its peers.
Enterprise Value |
|
To determine if Eli Lilly is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Eli Lilly's net worth research are outlined below:
Eli Lilly generated a negative expected return over the last 90 days | |
Over 83.0% of the company shares are owned by institutional investors | |
Latest headline from benzinga.com: Disposition of 278 shares by Gordon Brooks of Eli Lilly subject to Rule 16b-3 |
Eli Lilly uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Eli Lilly and. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Eli Lilly's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
6th of February 2024 Upcoming Quarterly Report | View | |
25th of April 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
6th of February 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Know Eli Lilly's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Eli Lilly is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Eli Lilly and backward and forwards among themselves. Eli Lilly's institutional investor refers to the entity that pools money to purchase Eli Lilly's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | Geode Capital Management, Llc | 2024-09-30 | 17.1 M | State Farm Mutual Automobile Ins Co | 2024-09-30 | 12.6 M | International Assets Investment Management, Llc | 2024-09-30 | 12.5 M | Norges Bank | 2024-06-30 | 11 M | Bank Of America Corp | 2024-06-30 | 10.8 M | Wellington Management Company Llp | 2024-06-30 | 10.8 M | Capital Research Global Investors | 2024-09-30 | 9.3 M | Northern Trust Corp | 2024-09-30 | 8.2 M | Legal & General Group Plc | 2024-06-30 | 7.1 M | Lilly Endowment Inc | 2024-09-30 | 96.9 M | Vanguard Group Inc | 2024-09-30 | 73.8 M |
Follow Eli Lilly's market capitalization trends
The company currently falls under 'Mega-Cap' category with a total capitalization of 708.83 B.Market Cap |
|
Project Eli Lilly's profitablity
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | 0.10 | 0.14 | |
Return On Capital Employed | 0.28 | 0.25 | |
Return On Assets | 0.08 | 0.12 | |
Return On Equity | 0.49 | 0.26 |
When accessing Eli Lilly's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Eli Lilly's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Eli Lilly's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Eli Lilly's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Eli Lilly and. Check Eli Lilly's Beneish M Score to see the likelihood of Eli Lilly's management manipulating its earnings.
Evaluate Eli Lilly's management efficiency
Eli Lilly has Return on Asset of 0.1395 % which means that on every $100 spent on assets, it made $0.1395 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.6532 %, implying that it generated $0.6532 on every 100 dollars invested. Eli Lilly's management efficiency ratios could be used to measure how well Eli Lilly manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Eli Lilly's Return On Tangible Assets are fairly stable compared to the past year. Return On Assets is likely to rise to 0.12 in 2024, whereas Return On Capital Employed is likely to drop 0.25 in 2024. At this time, Eli Lilly's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 40.2 B in 2024, whereas Non Currrent Assets Other are likely to drop slightly above 2.9 B in 2024.Last Reported | Projected for Next Year | ||
Book Value Per Share | 12.07 | 6.21 | |
Tangible Book Value Per Share | (1.09) | (1.04) | |
Enterprise Value Over EBITDA | 63.86 | 36.96 | |
Price Book Value Ratio | 48.71 | 51.15 | |
Enterprise Value Multiple | 63.86 | 36.96 | |
Price Fair Value | 48.71 | 51.15 | |
Enterprise Value | 492.4 B | 517 B |
The decision-making processes within Eli Lilly are key to its success in a competitive market. By evaluating these processes, we assess the stock's potential for future gains.
Enterprise Value Revenue 18.0467 | Revenue 40.9 B | Quarterly Revenue Growth 0.204 | Revenue Per Share 45.368 | Return On Equity 0.6532 |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Eli Lilly insiders, such as employees or executives, is commonly permitted as long as it does not rely on Eli Lilly's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Eli Lilly insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Gordon Brooks over a week ago Disposition of 278 shares by Gordon Brooks of Eli Lilly subject to Rule 16b-3 | ||
Donald Zakrowski over six months ago Payment of 2142 shares by Donald Zakrowski of Eli Lilly subject to Rule 16b-3 | ||
Donald Zakrowski over a year ago Sale by Donald Zakrowski of 670 shares of Eli Lilly | ||
Alfonso Zulueta over a year ago Payment of 9674 shares by Alfonso Zulueta of Eli Lilly subject to Rule 16b-3 | ||
Alfonso Zulueta over a year ago Sale by Alfonso Zulueta of 7000 shares of Eli Lilly |
Eli Lilly Corporate Filings
F4 | 20th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 19th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
F3 | 18th of September 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
Eli Lilly Earnings per Share Projection vs Actual
Eli Lilly Corporate Directors
Kathi Seifert | Independent Director | Profile | |
Jamere Jackson | Independent Director | Profile | |
Juan Luciano | Lead Independent Director | Profile | |
Gabrielle Sulzberger | Independent Director | Profile |
Additional Tools for Eli Stock Analysis
When running Eli Lilly's price analysis, check to measure Eli Lilly's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eli Lilly is operating at the current time. Most of Eli Lilly's value examination focuses on studying past and present price action to predict the probability of Eli Lilly's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eli Lilly's price. Additionally, you may evaluate how the addition of Eli Lilly to your portfolios can decrease your overall portfolio volatility.